2018
DOI: 10.1093/annonc/mdy155
|View full text |Cite|
|
Sign up to set email alerts
|

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Abstract: NCT01958021.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

17
391
3
23

Year Published

2018
2018
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 555 publications
(434 citation statements)
references
References 10 publications
17
391
3
23
Order By: Relevance
“…At a median follow-up of 26.4 months, an improvement in PFS (25.3 vs 16.0 months; HR for progression or death was 0.56; 95% CI, 0.45-0.70) and improved ORR of 43% vs 29% was seen with ribociclib plus letrozole compared with letrozole alone. 29 Grade 3 or 4 adverse events were more common with the combination, including neutropenia (62% vs 1.2%), leukopenia (21.3% vs 0.9%), and abnormal liver function tests (10.2% vs 2.4%). 29 The phase III MONARCH trial studied the combination of abemaciclib either with an AI (letrozole or anastrozole) versus AI monotherapy as first-line treatment of women with advanced HR-positive, HER2-negative breast cancer.…”
Section: Systemic Therapy For Stage IV or Recurrent Metastatic Hr-posmentioning
confidence: 94%
“…At a median follow-up of 26.4 months, an improvement in PFS (25.3 vs 16.0 months; HR for progression or death was 0.56; 95% CI, 0.45-0.70) and improved ORR of 43% vs 29% was seen with ribociclib plus letrozole compared with letrozole alone. 29 Grade 3 or 4 adverse events were more common with the combination, including neutropenia (62% vs 1.2%), leukopenia (21.3% vs 0.9%), and abnormal liver function tests (10.2% vs 2.4%). 29 The phase III MONARCH trial studied the combination of abemaciclib either with an AI (letrozole or anastrozole) versus AI monotherapy as first-line treatment of women with advanced HR-positive, HER2-negative breast cancer.…”
Section: Systemic Therapy For Stage IV or Recurrent Metastatic Hr-posmentioning
confidence: 94%
“…The compound has been approved by a number of health authorities, including the United States Food and Drug Administration (US FDA) and the European Medicines Agency, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant. 1,2,3 Additional marketing authorizations are under review by health authorities worldwide.…”
Section: Introductionmentioning
confidence: 99%
“…This is less than the 10-to 16-month PFS results observed in first-line hormonal therapy control arms in modern-era CDKI trials but similar to the results for the aromatase inhibitor arms in the early aromatase inhibitor versus tamoxifen first-line trials. 9,[18][19][20] Although the CDKI studies reported PFS, this can be considered to be analogous to the duration of treatment because progression usually triggers a change in therapy. Key differences between a trial and a general population likely explain some or all of the PFS differences between our population cohorts and the trial populations.…”
Section: Discussionmentioning
confidence: 99%